| Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum AL Benedet, M Milà-Alomà, A Vrillon, NJ Ashton, TA Pascoal, F Lussier, ... JAMA neurology 78 (12), 1471-1483, 2021 | 323 | 2021 |
| Abnormal recruitment of extracellular matrix proteins by excess Notch3ECD: a new pathomechanism in CADASIL M Monet-Leprêtre, I Haddad, C Baron-Menguy, M Fouillot-Panchal, ... Brain 136 (6), 1830-1845, 2013 | 217 | 2013 |
| Cadasil and Carasil S Tikka, M Baumann, M Siitonen, P Pasanen, M Pöyhönen, ... Brain Pathology 24 (5), 525-544, 2014 | 209 | 2014 |
| Potassium channelopathy-like defect underlies early-stage cerebrovascular dysfunction in a genetic model of small vessel disease F Dabertrand, C Krøigaard, AD Bonev, E Cognat, T Dalsgaard, ... Proceedings of the National Academy of Sciences 112 (7), E796-E805, 2015 | 99 | 2015 |
| Reducing T imp3 or vitronectin ameliorates disease manifestations in CADASIL mice C Capone, E Cognat, L Ghezali, C Baron‐Menguy, D Aubin, L Mesnard, ... Annals of neurology 79 (3), 387-403, 2016 | 96 | 2016 |
| Transcranial magnetic stimulation as an efficient treatment for psychogenic movement disorders B Garcin, E Roze, F Mesrati, E Cognat, E Fournier, M Vidailhet, B Degos Journal of Neurology, Neurosurgery & Psychiatry 84 (9), 1043-1046, 2013 | 84 | 2013 |
| Dissection of synaptic pathways through the CSF biomarkers for predicting Alzheimer disease M Tible, Å Sandelius, K Höglund, A Brinkmalm, E Cognat, J Dumurgier, ... Neurology 95 (8), e953-e961, 2020 | 72 | 2020 |
| Cerebral venous thrombosis in inflammatory bowel diseases: eight cases and literature review E Cognat, I Crassard, C Denier, K Vahedi, MG Bousser International Journal of Stroke 6 (6), 487-492, 2011 | 69 | 2011 |
| Age and the association between apolipoprotein E genotype and Alzheimer disease: A cerebrospinal fluid biomarker–based case–control study H Saddiki, A Fayosse, E Cognat, S Sabia, S Engelborghs, D Wallon, ... PLoS medicine 17 (8), e1003289, 2020 | 67 | 2020 |
| Are ketogenic diets promising for Alzheimer’s disease? A translational review M Lilamand, B Porte, E Cognat, J Hugon, F Mouton-Liger, C Paquet Alzheimer's research & therapy 12, 1-10, 2020 | 66 | 2020 |
| Early white matter changes in CADASIL: evidence of segmental intramyelinic oedema in a pre-clinical mouse model E Cognat, S Cleophax, V Domenga-Denier, A Joutel Acta neuropathologica communications 2, 1-16, 2014 | 62 | 2014 |
| Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies MC Gonzalez, NJ Ashton, BF Gomes, DA Tovar-Rios, F Blanc, TK Karikari, ... JAMA neurology 79 (1), 32-37, 2022 | 51 | 2022 |
| Archetypal Arg169Cys mutation in NOTCH3 does not drive the pathogenesis in cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy via a loss … E Cognat, C Baron-Menguy, V Domenga-Denier, S Cleophax, ... Stroke 45 (3), 842-849, 2014 | 49 | 2014 |
| Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease A Boza-Serrano, A Vrillon, K Minta, A Paulus, L Camprubí-Ferrer, ... Acta neuropathologica 144 (5), 843-859, 2022 | 36 | 2022 |
| Efficacy of endovascular therapy in acute ischemic stroke depends on age and clinical severity R Le Bouc, F Clarençon, E Meseguer, B Lapergue, A Consoli, G Turc, ... Stroke 49 (7), 1686-1694, 2018 | 36 | 2018 |
| Translational Biomarkers in Aging and Dementia (TRIAD) study, Alzheimer’s and Families (ALFA) study, and BioCogBank Paris Lariboisière cohort. Differences between plasma and … AL Benedet, M Milà-Alomà, A Vrillon, NJ Ashton, TA Pascoal, F Lussier, ... JAMA Neurol 78 (12), 1471-1483, 2021 | 34 | 2021 |
| CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease F Mouton-Liger, J Dumurgier, E Cognat, C Hourregue, H Zetterberg, ... Alzheimer's research & therapy 12, 1-10, 2020 | 31 | 2020 |
| Preventing post-lumbar puncture headache E Cognat, B Koehl, M Lilamand, S Goutagny, A Belbachir, ... Annals of emergency medicine 78 (3), 443-450, 2021 | 28 | 2021 |
| CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease A Boumenir, E Cognat, S Sabia, C Hourregue, M Lilamand, A Dugravot, ... Alzheimer's research & therapy 11, 1-9, 2019 | 23 | 2019 |
| Biomarker profiles of Alzheimer’s disease and dynamic of the association between cerebrospinal fluid levels of β-amyloid peptide and tau ASM Lafirdeen, E Cognat, S Sabia, C Hourregue, M Lilamand, ... PLoS One 14 (5), e0217026, 2019 | 21 | 2019 |
